Surgeons often must rely on what they see with the naked eye, and this can lead to poor surgical outcomes and preventable complications, such as in colorectal cancer surgery where there are 15% severe complications with a 35% associated mortality rate. Hypervision Surgical (HVS) have developed patent-pending hyperspectral imaging technology to capture and analyse spectral information far beyond human perception. By harnessing artificial intelligence and clinical edge computing, they extract ultra-fast tissue analytics (‘Hyperspectral Intelligence’), which unlock valuable insights from the spectral tissue ‘fingerprint’, empowering surgeons to make confident decisions with enhanced precision and ultimately improving patient outcomes.
Michael Ebner is the CEO and co-founder and co-developed the original patent-pending technology before spinning out HVS. He recounts that: “The Academy has been instrumental in supporting HVS since the inception of the company.”
Michael sees the Shott Scale-Up Accelerator as an ideal opportunity to leverage the Academy's unique network and structured programme to support HVS at its current stage. He thinks: “Engaging with coaches/mentors/networks will help me identify blind spots, help me to acquire vital foresight and leadership skills, and I'm especially interested in a US-facing leadership course to unlock HVS' full commercial potential for enhanced surgery and patient care.”
Over two-and-a-half years HVS have grown from four co-founders to 24 members of staff (14 full-time). They have created a more professional board to support their growth. This will help HVS through this new phase of growth over the next 12 months. This includes achieving regulatory clearance (UKCA/FDA expected within 6 months), use by early-adopters in first clinical evaluation studies, and negotiation of commercial deals with potential strategic partners.
